EMA Authorised: Agilus (dantrolene sodium, hemiheptahydrate) — Norgine B.V.

View source ↗

Summary

EMA authorised Agilus for malignant hyperthermia, with active substance dantrolene sodium hemiheptahydrate, manufactured by Norgine B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Hyperthermia

Drugs mentioned

• Agilus (dantrolene sodium, hemiheptahydrate)

Snippet

Status: Authorised. Therapeutic area: Malignant Hyperthermia. MAH: Norgine B.V.. Decision date: 29/05/2024